Novo Nordisk (NVO) Slashes Wegovy Price in India Up to 37% as Board Vote Nears; U.S. Access Deal Sets 2026 Shift — Nov. 11, 2025

Date: November 11, 2025

NYSE:NVO · Pharmaceuticals
Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Shares of Metsera, Inc. slumped on Monday after the obesity‑drug developer said it will proceed with a sweetened takeover by Pfizer that ends a high‑stakes bidding war with Novo Nordisk. Metsera accepted Pfizer’s revised offer late Friday; Novo dropped out over the weekend. In early U.S. trading today, MTSR fell ~15% as investors recalibrated expectations around the final deal structure.
10 November 2025
····
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Novo Nordisk and Pfizer Stocks Today (Nov. 10, 2025): Pfizer Clinches $10B Metsera Deal as Novo Rises on Exit and India Brand Move

Summary: On Monday, Pfizer said it will acquire obesity‑drug developer Metsera in a deal worth up to $10 billion, while Novo Nordisk shares climbed after bowing out of the bidding war. Governance drama around Novo’s board intensified as Norway’s $1.5 trillion sovereign wealth fund said it would abstain from key votes this week. Separately, Novo struck a distribution pact in India to sell a new branded version of its semaglutide weight‑loss shot. Reuters+3Reuters+3Reuters+3
10 November 2025
··
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Late Friday, Metsera accepted a sweetened offer from Pfizer: $65.60 per share in cash plus a contingent value right of up to $20.65 per share, valuing the biotech at up to $10 billion. On Saturday, Novo Nordisk said it would not increase its bid and exited the race, citing legal and regulatory risks tied to its two‑step proposal. Metsera’s board said Pfizer’s amended agreement carries lower antitrust risk and recommended shareholders approve it at a Nov. 13 meeting. PR Newswire+1
8 November 2025
···
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer Inc. has secured a definitive agreement to acquire weight‑loss biotech Metsera in a transaction valued at up to $10 billion, ending a high‑stakes bidding war with Novo Nordisk and positioning Pfizer squarely back in the fast‑growing obesity market. Metsera accepted Pfizer’s revised offer late Friday; Novo said today it would not raise its competing bid. Reuters
8 November 2025
···
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 7, 2025): NVO Slips as U.S. Wegovy/Ozempic Price Cuts Take Center Stage; Medicare Coverage, FTC Scrutiny and Metsera Bid in Focus

Summary: Novo Nordisk’s U.S.-listed shares traded lower on Friday after the company and Eli Lilly agreed to cut U.S. prices on GLP‑1 medicines to expand access, including under Medicare. The deal introduces near‑term revenue pressure but could lift volumes over time. Investors are also watching a court decision that favored Novo in its bid for obesity biotech Metsera and closely reading this week’s Q3 update and guidance cut. Investopedia+3Reuters+3Novo Nordisk+3
7 November 2025
··
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

NVO Stock Today (Nov 6, 2025): Novo Nordisk volatile as White House pricing deal reshapes GLP‑1 market—what it means for Wegovy, Ozempic and investors

TL;DR: Novo Nordisk’s U.S.‑listed shares swung after the White House announced a pricing-and-access deal with Novo and Eli Lilly that expands Medicare coverage for anti‑obesity drugs and cuts out‑of‑pocket costs. As of 17:51 UTC, NVO traded around $47.30, down ~2.4% on the day. The company confirmed a Medicare Part D pilot beginning in 2026, lower U.S. prices in Medicare/Medicaid and cash channels, and a three‑year tariff exemption—and flagged a low single‑digit drag to 2026 global sales growth. GlobeNewswire
6 November 2025
··
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (Nov 6, 2025): NVO steadies as White House GLP‑1 pricing deal lands; $10B Metsera bidding war heats up

Novo Nordisk stock traded around $47.36 as of 17:52 UTC, after opening at $47.75 and moving between $46.91–$49.49 on heavy volume. The tape is being driven by two big headlines: a White House pricing agreement that expands access to GLP‑1 drugs across Medicare/Medicaid and a new direct‑to‑consumer channel, and a $10 billion bidding battle with Pfizer for obesity‑drug startup Metsera.
6 November 2025
·
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

1) Court clears the way for Metsera to pivot to Novo’s richer bid.On Wednesday evening, the Delaware Chancery Court denied Pfizer’s TRO request that sought to keep Metsera bound to its earlier merger agreement with Pfizer. In a same‑day statement, Pfizer argued the decision “does not address the merits” and vowed to pursue its claims in parallel antitrust litigation. BioSpace’s Thursday write‑up and the company’s press release confirm the ruling and Pfizer’s plan to keep fighting. BioSpace+1
6 November 2025
····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Just a year ago, Novo Nordisk – buoyed by the meteoric success of its weight-loss injection Wegovy – briefly eclipsed all other European companies in market valuereuters.com. The Danish pharmaceutical giant enjoyed surging sales as Wegovy and its type-2 diabetes sibling Ozempic became global sensations, with millions seeking their dramatic weight-loss benefits. However, 2025 has seen a sharp reversal of fortune. A “slew of headwinds has shaken investor confidence” in Novo Nordisk’s once-dominant growth storystockanalysis.com. The company’s share price has plummeted nearly 50% year-to-date amid signs that demand growth is slowing and profitability is coming under pressurereuters.com.
5 November 2025
···
Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera (MTSR) Stock Soars 20% Amid $10B Bidding War – Pfizer vs Novo Nordisk Face Off

Metsera’s stock has been on a meteoric rise in recent weeks, capped by a 20% jump on November 4, 2025 alonereuters.comreuters.com. The share price is now hovering in the low $70sreuters.com, a remarkable increase from just around $30–$33 in mid-September before any takeover talks emergedprnewswire.com. In fact, over the past 52 weeks the stock ranged from a low of about $12.30 to a new high of $73.60 set on November 4reuters.com – reflecting hundreds of percent in gains for early investors.
4 November 2025
···
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer Stock’s Wild November Ride: Earnings Beat, Obesity Drug Battle & Bold Forecasts

Pfizer’s share price has been trading near multi-year lows, reflecting both recent challenges and cautious investor sentiment. As of Nov 4, 2025, PFE sits around $24.5, roughly the midpoint of its 52-week rangemarketbeat.com. The stock hit a 12-month low just above $20 in early 2025 amid concern over falling COVID revenues, then rebounded. In late September and early October, Pfizer climbed back to the upper $20s following its government pricing deal announcementmarketbeat.com, temporarily trading above its 50-day and 200-day moving averages. However, disappointing industry news and the uncertainty of the Metsera takeover battle led to profit-taking. By early November, Pfizer’s 50-day average converged with its 200-day averagemarketbeat.com, indicating a lack of a strong trend. This technical “flatline” suggests the stock is searching for direction, consolidating after its volatile swings.
4 November 2025
·····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market sharereuters.com. Novo’s new CEO Mike Doustdar and the company’s controlling foundation have pushed for bolder moves after days of sliding market performancereuters.comreuters.com. In late October, Novo – which had already agreed a separate $5 billion deal to buy diabetes biotech Akero – suddenly “launched a bid…valuing [Metsera] at some $9 billion and crashing Pfizer’s deal”reuters.com. This was weeks after Novo’s top shareholder overhauled its board to demand a faster turnaround in the weight-loss arenareuters.comreuters.com.
4 November 2025
···
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer delivered a positive surprise in Q3 2025, topping earnings and revenue expectations even as its overall results declined from a year ago. Adjusted earnings per share came in at $0.87, comfortably above consensusreuters.com. This was achieved on quarterly revenue of about $16.7 billion, which, while ~6% lower than the same period last year, slightly exceeded analysts’ forecastsstocktwits.comreuters.com. The decline was largely anticipated due to the sharp drop in COVID-19 product demand, but stronger-than-expected sales in other areas helped Pfizer beat the Street’s estimates.
4 November 2025
···
Palantir’s Shocking Reinvention: From Secretive Spy Tech to $400B Cult Lifestyle Brand

Palantir’s ‘Otherworldly’ Earnings & Wegovy Deal Buzz Spark After-Hours Stock Fireworks

Palantir Technologies delivered a record third quarter, easily topping analyst expectations on both revenue and profit. The company’s revenue jumped 63% year-over-year to $1.18 billion, with adjusted earnings of $0.21 per share – well above estimates of about $0.17investopedia.com. CEO Alex Karp credited booming demand for Palantir’s Artificial Intelligence Platform, especially among commercial customers. U.S. commercial revenue more than doubled to $397 million, outpacing even robust growth in government contractsinvestopedia.com. Karp hailed the commercial business as an “absolute juggernaut” and lauded the company’s “otherworldly” AI-driven growth in a letter to investorsinvestopedia.com.
4 November 2025
·······
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Analyst outlook & forecast: Long-term, analysts model robust growth. For example, one financial model projects ~18% revenue CAGR: ~$3.3 billion in sales by 2028 and ~$261 million net incomesimplywall.st. Another estimate sees revenue rising from ~$2.35 B in 2025 to ~$3.34 B by 2027tipranks.com, and free cash flow turning positive in 2025simplywall.st. These forecasts assume continued momentum in weight-loss/metabolic services plus gains in new verticals. Yet many investors note the high valuation and regulatory/legal risks. Community “fair value” estimates vary widely due to uncertaintysimplywall.st. Key analysts maintain Holds in light of decelerating growth and competition, though they acknowledge solid subscription volumes and expanding offeringstipranks.com.
3 November 2025
···
1 … 4 5 6 7 8
Follow on Google News
Add as preferred source Open in Google News